The Motley Fool EN

Why ImmunityBio Stock Is Down More Than 20% Today

Perhaps the company's management will be more careful after a third regulatory run-in.

Mar 24, 2026 &03392424202631; 16:39 UTC www.fool.com Trending 4/5

Read original on www.fool.com ↗

↘

Negative for markets

Sentiment score: -75/100

High impact Immediate effect (hours)

WHAT THIS MEANS

ImmunityBio stock crashed >20% due to a third regulatory setback, a company-specific negative catalyst. The broader market is slightly down (-0.39%) with elevated VIX (26.41), indicating the move is already reflected in the stock price after 37 minutes.

AI CONFIDENCE

35% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

IBRX

IBRXStock

High volatility expected

Stock already down >20% in 37 minutes; regulatory news is fully priced in. Further downside or bounce is unpredictable without new catalysts. Trading now is chasing a move, not leading it.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

SKIP THIS TRADE. The move is already priced in; entry now is either a dead-cat bounce or capitulation. Wait for stabilization or new fundamental news before considering a position. Risk/reward is unfavorable at current volatility. [PRICED_IN] [MOVE:0%]

KEY SIGNALS

Third regulatory setback signals management/execution risk20%+ intraday move = liquidity exhaustion, high volatility aheadNews is 37 minutes old — market has already digested the shockVIX elevated but S&P 500 resilient — sector-specific pain, not systemic

SECTORS INVOLVED

HealthcareBiotechnology

Analysis generated on Mar 24, 2026 at 17:15 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by The Motley Fool. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Why ImmunityBio Stock Is Down More Than 20% Today

RELATED INTELLIGENCE